Tubulis

PROSION

This deep-tech company develops small molecule inhibitors to target undruggable proteins for patients with cancer and other serious diseases.

Catena Biosciences

This deep-tech company develops protein conjugation technology and multi-payload conjugates to create targeted therapeutics for patients with oncology and autoimmune diseases.

Tacalyx

This company develops antibody-based therapeutics targeting tumour associated carbohydrate antigens for the treatment of solid tumours in cancer patients.

Phost'in Therapeutics

This deep-tech company develops small molecule glycocalyx modifiers to treat patients with aggressive solid tumours by restoring immune responses against cancer cells.

Type6 Therapeutics

This deep-tech company develops kinase inhibitors for cancer treatment, intercepting enzymes in their inactive states to address drug resistance for patients with aggressive tumours.

T-CURX

This biotech company develops non-viral CAR-T cell therapies to treat patients with leukaemia, lymphoma and solid tumours.

DualTPharma

This company develops bacteria-based drug delivery systems to transport immunotherapies into solid tumours for cancer patients.

Circle Pharma

This deep-tech company develops macrocycle-based therapies to treat cancer and other serious illnesses for patients requiring targeted medical treatments.